Chiquitha D Crews

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 4

Top Topics

Respiratory Syndrome Coronavirus

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Janet K Yamamoto, Lekshmi K Edison, Dawne K Rowe-Haas, Tomomi Takano, Chen Gilor, Chiquitha D Crews, Apichai Tuanyok, Ananta P Arukha, Sayaka Shiomitsu, Heather D S Walden, Tsutomu Hohdatsu, Stephen Mark Tompkins, John Glenn Morris, Bikash Sahay, Subhashinie Kariyawasam
Both Feline Coronavirus Serotypes 1 and 2 Infected Domestic Cats Develop Cross-Reactive Antibodies to SARS-CoV-2 Receptor Binding Domain: Its Implication to Pan-CoV Vaccine Development. Viruses 15 (4) (2023)
Janet K Yamamoto, Lekshmi K Edison, Dawne K Rowe-Haas, Tomomi Takano, Chen Gilor, Chiquitha D Crews, Apichai Tuanyok, Ananta P Arukha, Sayaka Shiomitsu, Heather D S Walden, Tsutomu Hohdatsu, Stephen Mark Tompkins, John Glenn Morris, Bikash Sahay, Subhashinie Kariyawasam
Both Feline Coronavirus Serotypes 1 and 2 Infected Domestic Cats Develop Cross-Reactive Antibodies to SARS-CoV-2 Receptor Binding Domain: Its Implication to Pan-CoV Vaccine Development. Viruses 15 (4) (2023)
Janet K Yamamoto, Lekshmi K Edison, Dawne K Rowe-Haas, Tomomi Takano, Chen Gilor, Chiquitha D Crews, Apichai Tuanyok, Ananta P Arukha, Sayaka Shiomitsu, Heather D S Walden, Tsutomu Hohdatsu, Stephen Mark Tompkins, John Glenn Morris, Bikash Sahay, Subhashinie Kariyawasam
Both Feline Coronavirus Serotypes 1 and 2 Infected Domestic Cats Develop Cross-Reactive Antibodies to SARS-CoV-2 Receptor Binding Domain: Its Implication to Pan-CoV Vaccine Development. Viruses 15 (4) (2023)
Janet K Yamamoto, Lekshmi K Edison, Dawne K Rowe-Haas, Tomomi Takano, Chen Gilor, Chiquitha D Crews, Apichai Tuanyok, Ananta P Arukha, Sayaka Shiomitsu, Heather D S Walden, Tsutomu Hohdatsu, Stephen Mark Tompkins, John Glenn Morris, Bikash Sahay, Subhashinie Kariyawasam
Both Feline Coronavirus Serotypes 1 and 2 Infected Domestic Cats Develop Cross-Reactive Antibodies to SARS-CoV-2 Receptor Binding Domain: Its Implication to Pan-CoV Vaccine Development. Viruses 15 (4) (2023)